infliximab-dyyb
E850004
Infliximab-dyyb is a monoclonal antibody biosimilar to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
All labels observed (1)
| Label | Occurrences |
|---|---|
| infliximab-dyyb canonical | 2 |
How this entity was disambiguated
This entity first appeared as the object of triple T10214555 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: infliximab-dyyb Context triple: [Inflectra, hasGenericName, infliximab-dyyb]
-
A.
Taltz
Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
-
B.
Stelara
Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
-
C.
Humira
Humira is a widely used biologic medication (adalimumab) that treats various autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease by inhibiting tumor necrosis factor (TNF).
-
D.
Kevzara
Kevzara is a prescription monoclonal antibody medication (sarilumab) used to treat adults with moderate to severe rheumatoid arthritis by targeting the interleukin-6 (IL-6) receptor.
-
E.
Cosentyx
Cosentyx is a biologic medication (secukinumab) used to treat autoimmune inflammatory conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: infliximab-dyyb Target entity description: Infliximab-dyyb is a monoclonal antibody biosimilar to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
A.
Taltz
Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
-
B.
Stelara
Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
-
C.
Humira
Humira is a widely used biologic medication (adalimumab) that treats various autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease by inhibiting tumor necrosis factor (TNF).
-
D.
Kevzara
Kevzara is a prescription monoclonal antibody medication (sarilumab) used to treat adults with moderate to severe rheumatoid arthritis by targeting the interleukin-6 (IL-6) receptor.
-
E.
Cosentyx
Cosentyx is a biologic medication (secukinumab) used to treat autoimmune inflammatory conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis.
- F. None of above. chosen
Statements (51)
| Predicate | Object |
|---|---|
| instanceOf |
biologic medicinal product
ⓘ
biosimilar medicinal product ⓘ monoclonal antibody ⓘ |
| administeredBy | healthcare professional ⓘ |
| belongsToTherapeuticArea |
dermatology
ⓘ
gastroenterology ⓘ rheumatology ⓘ |
| biosimilarTo |
infliximab
ⓘ
linked to:
Remicade
|
| contraindicatedIn |
patients with moderate or severe heart failure
ⓘ
patients with severe infections ⓘ |
| hasATCClass | L04AB02 ⓘ |
| hasBlackBoxWarning |
malignancy
ⓘ
serious infections ⓘ |
| hasDosageForm | solution for intravenous infusion ⓘ |
| hasIndication |
active ankylosing spondylitis
ⓘ
active psoriatic arthritis ⓘ chronic severe plaque psoriasis ⓘ moderate to severe Crohn’s disease ⓘ moderate to severe rheumatoid arthritis ⓘ moderate to severe ulcerative colitis ⓘ steroid-dependent Crohn’s disease ⓘ steroid-dependent ulcerative colitis ⓘ steroid-refractory Crohn’s disease ⓘ steroid-refractory ulcerative colitis ⓘ |
| hasMechanismOfAction | TNF inhibitor ⓘ |
| hasMolecularType | chimeric monoclonal antibody ⓘ |
| hasNonproprietaryName | infliximab-dyyb ⓘ |
| hasPharmacologicalClass |
immunosuppressive agent
ⓘ
tumor necrosis factor alpha inhibitor ⓘ |
| hasRouteOfAdministration |
intravenous infusion
ⓘ
parenteral ⓘ |
| hasSpeciesComponents |
human
ⓘ
mouse ⓘ |
| hasTarget |
TNF-α
ⓘ
linked to:
tumor necrosis factor alpha
tumor necrosis factor alpha ⓘ |
| hasUSBrandName | Inflectra ⓘ |
| mayCause |
hypersensitivity reactions
ⓘ
infusion-related reactions ⓘ reactivation of latent tuberculosis ⓘ |
| regulatoryDesignation | biosimilar to Remicade ⓘ |
| requiresMonitoring |
hepatitis B virus reactivation
ⓘ
signs and symptoms of infection ⓘ tuberculosis status ⓘ |
| usedFor |
Crohn’s disease
ⓘ
ankylosing spondylitis ⓘ pediatric Crohn’s disease ⓘ pediatric ulcerative colitis ⓘ plaque psoriasis ⓘ psoriatic arthritis ⓘ rheumatoid arthritis ⓘ ulcerative colitis ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: infliximab-dyyb Description of subject: Infliximab-dyyb is a monoclonal antibody biosimilar to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.